Supporting your product—and your business—at every stage
Orally disintegrating tablets (ODTs) provide several advantages over conventional swallow tablets, including ease of use, convenience, and more efficient therapeutic action in some applications. This has led to increased interest in ODT formulations for a growing variety of pharmaceutical products, especially for some underserved patient populations (such as people with difficulty swallowing, those lacking convenient or safe access to drinking water, and geriatric and pediatric patients).
When you partner with SPI Pharma, you gain product distinction in crowded therapeutic markets where there is very little difference among competing products. By enabling you to create branded, differentiated line extensions, ODT technologies can help you bring valuable benefits to patients, enhance your product's life cycle—and increase your profits.
Are you ready to build a better brand and company image with a unique, easier-to-take form that satisfies the need of underserved patient populations? A line extension with our Pharmaburst® ODT platform and pharmaceutical life cycle management services offers advanced support for every stage of your product's life cycle.
Partner with us to:
- Formulate your ODT product to meet specific patient and dosage requirements.
- Facilitate the development of your ODT product with our data package offering.
- Solve your complex formulation challenges with customized solutions developed by our skilled pharmacists and chemists.
- Energize your drug portfolio with the unique options available through our Pharmasolutions drug development and testing service.
For more information about our complete pharmaceutical life cycle management solutions, please contact us.